United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

(Reuters) -Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.

Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 billion

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) driven by its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, as well as its business excluding BNT162b2(1). Additionally, Pfizer published this morning on its website the second-quarter 2021 earnings presentation and accompanying prepared remar

PFIZER REPORTS SECOND-QUARTER 2021 RESULTS

Moderna

The writing could already be on the wall.

3 Big Hints That COVID Vaccine Booster Doses Are on the Way

Johnson & Johnson

In the face of a comprehensive global tax agreement intended to inhibit tax avoidance opportunities, industry executives and lobbyists are mounting a quiet campaign to push back against the measure, the Wall Street Journal reports.  This time, the pharma industry is using the goodwill garnered by the rapid deployment of COVID-19 vaccines as the new negotiating tool.

Pharma Heavyweights, Including Pfizer And JNJ Trying To Push Global Tax Deal Amid COVID-19 Role: WSJ

Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Pfizer (PFE)

Pfizer (PFE) reports Q2 earnings before market open on July 28. Can it maintain soaring earnings and revenue growth amid the global COVID-19 pandemic?

Pfizer Q2 FY 2021 Earnings Report Preview: What to Look For

Pfizer (NYSE: PFE) is scheduled to report its Q2 2021 results on Wednesday, July 28. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine.

Is Pfizer Stock Set To See Higher Levels Post Q2 Results?

The giant drugmaker just landed another big supply deal.

200 Million More Reasons to Buy Pfizer Stock

AstraZeneca

The study follows another by Oxford University that found taking an AstraZeneca vaccine shot followed by a Pfizer shot created a high immune repsonse.

Mixed Astra-Zeneca-Pfizer Vaccine Boosts Covid Antibody Levels, Korea Study Finds

The studies aim to spot rare side effects of the COVID-19 vaccine in younger recipients.

Pfizer and Moderna expanding vaccine studies in children 5 to 11, report says

The vaccine makers were reportedly asked by the Food and Drug Administration to expand the size of their ongoing trials.

Pfizer And Moderna Reportedly Expanding Covid Vaccine Studies Of Children To Better Understand Rare Side Effects

Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) will expand the size of ongoing COVID-19 vaccine trials in children ages five to 11 to detect potential rare side effects, The New York Times reports. What Happened: The trial expansions come at the urging of the FDA, a precautionary measure designed to detect rare side effects, including heart inflammation problems that turned up in vaccinated people younger than 30.

FDA Asks Pfizer/BioNTech, Moderna To Expand COVID-19 Vaccine Trials In Children: NYT

In terms of hospitalisation and death, COVID is becoming a pandemic of the unvaccinated. Achieving herd immunity is critical not only for reopening economies but also to mitigate long-term chronic health problems from those recovered from COVID.

Pfizer/BioNTech COVID Vaccine(s) And The Future

Boeing

McDonald's

Tilray Brands

The five largest U.S. traded companies report June-quarter earnings this week, beginning Monday evening with Tesla.

Earnings Previews: Boeing, McDonald's, Pfizer, Tilray

Citi's Andrew Baum also thinks chances are good that annual boosters will be needed, even if risk of the disease drops.

Covid Boosters Are Coming This Year for People 50 and Older, Analyst Predicts

Clorox

Costco

Intel

Main Street Capital

Morgan Stanley

Realty Income Corp

Omega Healthcare Investors

ONEOK

Pinnacle West Capital

PPG Industries

STAG Industrial

Valero Energy

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: July 27-August 9, 2021

All eyes are on Pfizer versus the delta variant.

Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad

Apple

Amazon

Tesla

Exxon Mobil

Second-quarter earnings season continues with results from Tesla, Apple, Microsoft, Amazon, Alphabet, Facebook, PayPal, Visa, T-Mobile, Pfizer, AMD, Exxon Mobil, and many more.

Apple, Tesla, Amazon, Exxon Mobil, Pfizer, and Other Stocks to Watch This Week

AbbVie

CVS Health

These stocks are cheap, but their underlying businesses are solid.

3 Value Stocks to Buy for the Second Half of 2021

Once again, their high efficacy could mean more market share.

This News May Hand the Vaccine Market Over to Pfizer and Moderna

We hope this mid-year letter finds you, your family, and your colleagues healthy and well. Here in Boston, GMO's headquarters, the streets are filling up with summer tourists, restaurants are crowded, our beloved Red Sox are in first place and playing to capacity-filled audiences in Fenway Park, and, in the worst backhanded compliment yet, commutes are miserable again – in other words, things look like they are getting back to normal.

GMO's 2021 Mid-Year Letter: Equity Allocation Strategies

Arvinas Inc

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas.

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

The federal government has bought an additional 200 million COVID-19 vaccine doses that are expected to be delivered starting in October 2021.

US buys 200M more doses of Pfizer vaccine, option for ‘updated version'

Previous estimates indicated the Pfizer shot was only moderately less protective against Delta, though all studies indicate a high level of protection against hospitalization and severe illness.

Pfizer Shot Just 39% Effective Against Delta Infection, But Largely Prevents Severe Illness, Israel Study Suggests

The U.S. government has purchased an additional 200 million doses of the Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) COVID-19 Vaccine. The incremental doses will be delivered from October 2021 through April 2022.

News for Pfizer Stock (PFE)